<div id="readability-page-1"><p>In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals, with a price target of <span id="expert-recommendation-target">$97.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Rahimi covers the Healthcare sector, focusing on stocks such as Cytokinetics, Climb Bio, and LB Pharmaceuticals, Inc.. According to TipRanks, Rahimi has an average return of <span>33.8%</span> and a 49.49% success rate on recommended stocks. </p> <p>Crinetics Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $86.00.</p></div>

CRNX

ARKG

<p>Piper Sandler analyst Yasmeen Rahimi has maintained a Buy rating on Crinetics Pharmaceuticals (CRNX) with a price target of $97.00. Rahimi, who specializes in the Healthcare sector, has an average return of 33.8% and a success rate of 49.49% on her stock recommendations. The analyst consensus for Crinetics Pharmaceuticals is a Strong Buy, with a price target consensus of $86.00.</p>

Tip Ranks

Crinetics Pharmaceuticals

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

SPDR S&P Biotech

VG Health

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

iShares US Pharma

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Piper Sandler Cos

Cytokinetics

Climb Bio

LB Pharmaceuticals

Piper Sandler Remains a Buy on Crinetics Pharmaceuticals (CRNX)